Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medivation Plans “Aggressive” Timeline For Alzheimer’s, Huntington’s NDAs

This article was originally published in The Pink Sheet Daily

Executive Summary

Dimebon safety profile compares favorably to Aricept, Exelon and Razadyne, CEO says.

You may also be interested in...

Alzheimer’s Drug Development Comparable To Cancer 50 Years Ago, Says Targacept CEO

Biomarkers and diagnostic tools must be developed to allow drug manufacturers to target Alzheimer’s disease modification, BioInvestor Forum panelists say.

Prestwick's Xenazine Faces Advisory Committee Review

Huntington's disease treatment tetrabenazine received an FDA "approvable" letter March 24.

Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007

Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts